STOCK TITAN
  1. Home
  2. Sec-filings
  3. PIII
  4. [Form 4/A] P3 Health Partners Inc. Amended Insider Trading Activity

Director at P3 Health Partners (PIII) awarded 2,000 RSUs in Form 4/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

P3 Health Partners Inc. director reports an amended equity grant. The filing shows an acquisition of 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, leaving the director with 6,331 Class A shares beneficially owned directly after the transaction.

The RSUs were granted under the company’s 2021 Incentive Award Plan and each RSU represents one share of Class A common stock. They vest upon the earlier of P3 Health Partners’ 2026 annual stockholder meeting or the one-year anniversary of the grant date. The amendment corrects the previously reported post‑transaction holdings, which were originally stated on a pre–reverse‑split basis following the company’s 1‑for‑50 reverse stock split effective April 11, 2025.

Positive

  • None.

Negative

  • None.
Insider Kazarian Gregory N.
Role Director
Type Security Shares Price Value
Grant/Award Class A Common Stock 2,000 $0.00 $0.00
Holdings After Transaction: Class A Common Stock — 6,331 shares (Direct)
Footnotes (2)
  1. F1. Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest upon the earlier of the Company's 2026 annual stockholder meeting and the one-year anniversary of the grant date.
  2. F2. This amended Form 4 is being filed to correct Column 5 of Table I, which inadvertently reported the number of securities beneficially owned by the Reporting Person prior to the Company's 1-for-50 reverse stock split, which became effective on April 11, 2025. This amended Form 4 is being filed solely to correct the number of securities beneficially owned by the Reporting Person following the reverse stock split.

FAQ

What insider transaction did P3 Health Partners (PIII) disclose in this Form 4/A?
The filing reports that a director of P3 Health Partners Inc. acquired 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0 per share.

How many P3 Health Partners (PIII) shares does the director own after this transaction?
Following the reported RSU grant and the correction in this amendment, the director is shown as beneficially owning 6,331 shares of P3 Health Partners Inc. Class A common stock directly.

When do the new RSUs for P3 Health Partners (PIII) vest?
The 2,000 RSUs vest upon the earlier of P3 Health Partners Inc.'s 2026 annual stockholder meeting and the one-year anniversary of the August 6, 2025 grant date.

What plan governs the RSU grant reported by P3 Health Partners (PIII)?
The restricted stock units were granted under the P3 Health Partners Inc. 2021 Incentive Award Plan, with each RSU representing one share of Class A common stock.

Why is this an amended Form 4/A for P3 Health Partners (PIII)?
The amendment corrects Column 5 of Table I, which previously showed the director’s beneficially owned shares before P3 Health Partners Inc.’s 1-for-50 reverse stock split that became effective on April 11, 2025. The revised filing is solely to state the correct number of shares owned after the reverse split.

Does the P3 Health Partners (PIII) director hold the reported shares directly or indirectly?
The filing identifies the 6,331 shares of Class A common stock as being held in direct ownership by the reporting director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kazarian Gregory N.
(Last) (First) (Middle)
C/O P3 HEALTH PARTNERS INC.
2370 CORPORATE CIRCLE, SUITE 300
(Street)
HENDERSON NV 89074
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
P3 Health Partners Inc. [ PIII ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/08/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 08/06/2025 A 2,000(1) A $0 6,331(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest upon the earlier of the Company's 2026 annual stockholder meeting and the one-year anniversary of the grant date.
2. This amended Form 4 is being filed to correct Column 5 of Table I, which inadvertently reported the number of securities beneficially owned by the Reporting Person prior to the Company's 1-for-50 reverse stock split, which became effective on April 11, 2025. This amended Form 4 is being filed solely to correct the number of securities beneficially owned by the Reporting Person following the reverse stock split.
Remarks:
/s/Todd Smith, Chief Legal Officer, as attorney-in-fact 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR